Nordic American Tankers Limited Common Stock vs Nuwellis Inc — how do they compare? Nordic American Tankers Limited Common Stock trades at $8.2 (market cap $1.86B), while Nuwellis Inc trades at $0.55 (market cap $2.00M). The key difference: Nordic American Tankers Limited Common Stock is far larger — about 930× Nuwellis Inc's market cap, and Nordic American Tankers Limited Common Stock pays a 12.29% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nordic American Tankers Limited Common Stock for 0 Days and Nuwellis Inc for 27 Days on average.
| NAT | NUWE | |
|---|---|---|
Market Cap | $1.86B | $2.00M |
Volume | 5,330,493 | 172,259 |
Sector | Industrials | Health |
52-Week High | $8.79 | $146.65 |
52-Week Low | $3.26 | $0.53 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $2.13B | -$1.72M |
Dividend Yield | 12.29% | — |
Signals from Pluang's Aura AI — not financial advice
NAT trades at $8.79, matching its 52-week high, reflecting strong momentum amid favorable tanker market conditions. The stock shows robust fundamentals with a 33.34% net income margin and 25.66% ROE for 2026, while Q2 2026 EPS beat expectations. Technical indicators are neutral, with support and resistance clustered around $9. Recent news highlights surging spot rates and insider buying by the Hansson family, underscoring confidence in near-term prospects.
Outlook is positive due to elevated freight rates and earnings growth, but risks include volatility in tanker rates and geopolitical tensions. Analysts are mixed with a $3.50 consensus target, suggesting caution despite operational strength. The stock's high yield and momentum offer appeal, though sustainability of current rates remains a key monitorable.
NUWE trades at $0.621, down 7.35% today, with a bearish technical signal despite oversold RSI readings. The company shows revenue growth with 2026 revenue reaching $9M, but continues to post significant losses with a -125.63% net income margin. Recent positive developments include strong Aquadex console adoption and expanded pediatric footprint, though cash flow remains negative requiring ongoing financing.
The outlook remains challenging with persistent losses and negative cash flow offset by promising commercial momentum. Investment opportunity hinges on the company's ability to achieve profitability while risks include execution challenges and dependence on financing. Analyst sentiment is mixed with equal buy/hold ratings reflecting the high-risk, high-reward nature of this medical technology stock.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Nordic American Tankers Limited is a Bermuda-based shipping company specializing exclusively in Suezmax crude-oil tankers, which it charters in the spot and period markets on international routes. The company has paid a dividend every quarter since 1997.
Read more on NAT →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →